Characteristics of patients entering the randomisation phase

CharacteristicsEtanercept 50 mg

(n = 7)

Placebo

(n = 6)

Mean difference (95% CI) or χ2 P value
Mean age, years (SE)73.4 (2.3)74.8 (2.9)1.4 (−6.7 to 9.5) yrs P = 0.7
Men, n (%)5 (71)4 (66)χ2 0.03 P = 0.9
Disease duration, years (SE)3.4 (1.2)5.3 (1.1)1.9 (−1.8 to 5.6) yrs P = 0.3
MoCA pts (SE)21.1 (1.6)24.7 (1.0)3.5 (−0.6 to 7.6) pts P = 0.09
FCSRT pts (SE)36.4 (4.3)46.8 (1.0)10.4 (−0.03 to 20.8) pts P = 0.051
RBANS pts (SE)82.0 (2.9)88.3 (4.6)6.3 (−0.5 to 18.0) pts P = 0.3
ADCS-ADL MCI pts (SE)38.9 (2.9)43.54.6 (−3.1 to 12.4) pts P = 0.2

CI: confidence interval; pts: patients; se: standard error; yrs: years